未登录

Z

Zofia Mazerska

Gdansk University of Technology

H指数:20

被引数:1,243

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Specific Impact of Acridine Antitumor Agents on the Survival Potency of the Selected Non-Cancerous Cells: Toxicological Insights

吖啶类抗肿瘤剂对选定非癌细胞的生存效力的特异性影响：毒理学见解

Biochemical and Biophysical Research Communications

IF2.2

2026-05-050

PRE

The interactions of Pu22 G-quadruplex, derived from c-MYC promoter sequence, with antitumor acridine derivatives-An NMR/MD combined study

源自c-MYC启动子序列的Pu22 G-四链体与抗肿瘤吖啶衍生物的相互作用——一项NMR/MD结合研究

MOLECULAR THERAPY NUCLEIC ACIDS

IF6.1

2025-06-010

OAAI

Distinct cellular uptake patterns of two anticancer unsymmetrical bisacridines and their metabolic transformation in tumor cells

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

IF3.1

2025-01-010

PRE

Unsymmetrical Bisacridines' Interactions with ABC Transporters and Their Cellular Impact on Colon LS 174T and Prostate DU 145 Cancer Cells

IF4.6

2024-11-260

OAAI

The interactions of monomeric acridines and unsymmetrical bisacridines (UAs) with DNA duplexes: an insight provided by NMR and MD studies

SCIENTIFIC REPORTS

IF3.9

2023-03-019

OAAI

Validated GC-MS method for determination of bisphenol a and its five analogues in dietary and nutritional supplements

MICROCHEMICAL JOURNAL

IF5.1

2022-09-0111

PRE

Acid-Base Equilibrium and Self-Association in Relation to High Antitumor Activity of Selected Unsymmetrical Bisacridines Established by Extensive Chemometric Analysis

IF4.6

2022-06-217

OAAI

Novel insights into conjugation of antitumor-active unsymmetrical bisacridine C-2028 with glutathione: Characteristics of non-enzymatic and glutathione S-transferase-mediated reactions

JOURNAL OF PHARMACEUTICAL ANALYSIS

IF8.9

2021-12-019

OAAI

Metabolic Profiles of New Unsymmetrical Bisacridine Antitumor Agents in Electrochemical and Enzymatic Noncellular Systems and in Tumor Cells

PHARMACEUTICALS

IF4.8

2021-04-018

OAAI

Electrochemical simulation of metabolic reduction and conjugation reactions of unsymmetrical bisacridine antitumor agents, C-2028 and C-2053

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

IF3.1

2021-04-016

PREAI

Design, synthesis and high antitumor potential of new unsymmetrical bisacridine derivatives towards human solid tumors, specifically pancreatic cancers and their unique ability to stabilize DNA G-quadruplexes

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

IF5.9

2020-10-0124

PREAI

Anticancer Imidazoacridinone C-1311 is Effective in Androgen-Dependent and Androgen-Independent Prostate Cancer Cells

IF3.9

2020-08-195

OAAI

Electrochemical and in silico approaches for liver metabolic oxidation of antitumor-active triazoloacridinone C-1305

JOURNAL OF PHARMACEUTICAL ANALYSIS

IF8.9

2020-08-017

OAAI

New Unsymmetrical Bisacridine Derivatives Noncovalently Attached to Quaternary Quantum Dots Improve Cancer Therapy by Enhancing Cytotoxicity toward Cancer Cells and Protecting Normal Cells

ACS APPLIED MATERIALS & INTERFACES

IF8.2

2020-03-2530

PREAI

The impact of lipophilicity on environmental processes, drug delivery and bioavailability of food components

MICROCHEMICAL JOURNAL

IF5.1

2019-05-0193

PREAI

Electrochemical simulation of metabolism for antitumor-active imidazoacridinone C-1311 and in silico prediction of drug metabolic reactions

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

IF3.1

2019-05-0112

PREAI

State of the art and prospects of methods for determination of lipophilicity of chemical compounds

TRAC-TRENDS IN ANALYTICAL CHEMISTRY

IF12

2019-04-0145

PREAI

Binary Mixtures of Selected Bisphenols in the Environment: Their Toxicity in Relationship to Individual Constituents

IF4.6

2018-12-0622

OAAI

Drug-drug interaction potential of antitumor acridine agent C-1748: The substrate of UDP-glucuronosyltransferases 2B7, 2B17 and the inhibitor of 1A9 and 2B7

PHARMACOLOGICAL REPORTS

IF3.8

2018-10-018

OAAI

Modulation of UDP-glucuronidation by acridinone antitumor agents C-1305 and C-1311 in HepG2 and HT29 cell lines, despite slight impact in noncellular systems

PHARMACOLOGICAL REPORTS

IF3.8

2018-06-014

PREAI